Sublingual isosorbide dinitrate in severe congestive heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Severe congestive heart failure (CHF) presents significant hemodynamic challenges.
• Effective management of CHF requires understanding drug actions on cardiovascular parameters.

Purpose of the Study:

• To characterize the hemodynamic effects of sublingual isosorbide dinitrate in patients with severe CHF.
• To identify predictors of response to isosorbide dinitrate in this patient population.

Main Methods:

• 17 patients with severe CHF received sublingual isosorbide dinitrate.
• Hemodynamic parameters including pulmonary capillary wedge pressure, pulmonary artery systolic pressure, right atrial pressure, arterial blood pressure, heart rate, and cardiac index were monitored.
• Patient responses were categorized based on the reduction in pulmonary capillary wedge pressure.

Main Results:

• Isosorbide dinitrate demonstrated maximal effect 30-60 minutes post-administration.
• A significant reduction in mean pulmonary capillary wedge pressure (28 to 20 mm Hg), pulmonary artery systolic pressure (55 to 43 mm Hg), and right atrial pressure (11 to 8 mm Hg) was observed (p < 0.01).
• 8 patients showed marked reduction in pulmonary capillary wedge pressure; responders had higher initial systolic blood pressure (133 vs. 102 mm Hg, p < 0.01) than non-responders.

Conclusions:

• Sublingual isosorbide dinitrate effectively reduces pulmonary pressures in severe CHF.
• Higher baseline systolic blood pressure may indicate a favorable response, but reliable prediction remains elusive.
• Further research is needed to identify precise predictors for isosorbide dinitrate efficacy in CHF management.